Yonsei Med J.  2006 Apr;47(2):201-206. 10.3349/ymj.2006.47.2.201.

Plasma Level of IL-6 and Its Relationship to Procoagulant and Fibrinolytic Markers in Acute Ischemic Stroke

• Song JW
• Song KS
• Choi JR
• Kim SY
• Rhee JH

• KMID: 1110743
• DOI: http://doi.org/10.3349/ymj.2006.47.2.201

Abstract

Procoagulant or impaired fibrinolytic states as well as inflammatory reactions mediated by cytokines are likely involved in the pathogenesis of acute ischemic stroke. We examined the potential relationship between interleukin 6 (IL-6) and hemostatic markers. The procoagulant and fibrinolytic states were assessed in 46 patients with acute stroke by measuring plasma levels of plasminogen activator inhibitor-1 (PAI-1), thrombin-antithrombin complex (TAT), and plasminogen-antiplasmin complex (PAP). Circulating IL-6 levels were measured using ELISA (Quantikine, R and D systems, MN, USA). Circulating IL-6 (mean, 26.5 pg/mL) and PAI-1 (mean, 19.9 ng/mL) levels were higher in patients with acute stroke than in healthy subjects (mean, 3.0 pg/mL, 10.4 ng/mL, respectively). TAT levels were statistically different according to the etiologic subtypes of stroke (atherogenic, 2.5 ng/mL; lacunar 3.2 ng/mL; cardiogenic 9.9 ng/mL, p = 0.021). Neither procoagulant levels nor fibrinolytic markers significantly correlated with circulating IL-6 levels. Our findings suggest that elevated proinflammatory cytokines during the initial hours of ischemic stroke may be an independent pathogenic factor or a consequence of the thrombotic event with no relationship to the procoagulant or fibrinolytic states.

Keyword

Stroke; cytokine; procoagulant; fibrinolysis

MeSH Terms

Thrombosis
Thrombolytic Therapy
Thrombin/chemistry
Plasminogen Activator Inhibitor 1/blood
Phospholipids/chemistry
Models, Statistical
Middle Aged
Male
Ischemia/*blood/*pathology
Interleukin-6/*blood/metabolism
Humans
Hemostasis
*Fibrinolysis
Female
Enzyme-Linked Immunosorbent Assay
Cytokines/metabolism
Coagulants/*metabolism
Cerebrovascular Accident/*blood/*pathology
Blood Coagulation Factors/metabolism
Antithrombins/chemistry
Aged
Acute Disease

Reference

1. Del Zoppo GJ, Zeumer H, Harker LA. Thrombolytic therapy in stroke : possibilities and hazards. Stroke. 1986. 17:595–607.

2. Tracy RP. Epidemiological evidence for inflammation in cardiovascular disease. Thromb Haemost. 1999. 82:826–831.

3. Scarpati EM, Sadler JE. Regulation of endothelial cell coagulant properties. Modulation of tissue factor, plasminogen activator inhibitors, and thrombomodulin by phorbol 12-myristate and tumor necrosis factor. J Biol Chem. 1989. 264:20705–20713.

4. Rabbani LE, Loscalzo J. Recent observations on the role of hemostatic determinants in the development of the atherothrombotic plaque. Atherosclerosis. 1994. 105:1–7.

5. Clark WM. Cytokines and reperfusion injury. Neurology. 1997. 49(5):Suppl 4. S10–S14.

6. Tsuda Y, Satoh K, Kitadai M, Takhashi T. Hemorheologic profiles of plasma fibrinogen and blood viscosity from silent to acute and chronic cerebral infarctions. J Neurol Sci. 1997. 147:49–54.

7. Castell JV, Andus T, Kunz D, Heinrich PC. Interleukin-6. The major regulator of acute phase protein synthesis in man and rat. Ann NY Acad Sci. 1989. 557:87–101.

8. Coull BM, Beamer NB, Clark WM. Elevated plasma interleukin-6 (IL-6) in acute stroke. Stroke. 1993. 24:183. (Abstract).

9. Fassbender K, Rossol S, Kammer T, Daffertshofer M, Wirth S, Dollman M, et al. Proinflammatory cytokines in serum of patients with acute cerebral ischemia: kinetics of secretion and relation to the extent of brain damage and outcome of disease. J Neurol Sci. 1994. 122:135–139.

10. Johansson A, Olsson T, Carlberg B, Karlsson K, Fagerlund M. Hypercorisolism after stroke-partly cytokine-mediated? J Neurol Sci. 1997. 147:43–47.

11. Vila N, Chamorro A. Cytokines and acute-phase response in acute stroke. Stroke. 1995. 26:1729–1731.

12. Remick DG, Kunkel RG, Larrick JW, Kunkel SL. Acute in vivo effects of human recombinant tumor necrosis factor. Lab Invest. 1987. 56:583–590.

13. Dobroski DR, Rabbani LE, Loscalzo J. Loscalzo J, Schfer AI, editors. The relationship between thrombosis and atherosclerosis. Thrombosis and Hemorrhage. 1998. Baltimore: Williams & Wilkins;837–861.

14. Marcovina SM, Zoppo A, Vigano-D'Angelo S, Di Cola G, D'Angelo A. Determination of serum levels of complement component C4b-binding protein: influence of age and inflammation. Int J Clin Lab Res. 1991. 21:171–175.

15. Esmon CT. The regulation of natural anticoagulant pathways. Science. 1987. 235:1348–1352.

16. Carr ME Jr, Zekert SL. Protein S and C4b-binding protein levels in patients with stroke: implications for protein S regulation. Haemostasis. 1993. 23:159–167.

17. Fisher M, Meiselman HJ. Hemorheological factors in cerebral ischemia. Stroke. 1991. 22:1164–1169.

18. Bick RL. Disseminated intravascular coagulation: pathophysiological mechanisms and manifestations. Semin Thromb Hemost. 1998. 24:3–18.

19. Geiser T, Sturzenegger M, Genewein U, Haeberli A, Beer JH. Mechanisms of cerebrovascular events as assessed by procoagulant activity, cerebral microemboli, and platelet microparticles in patients with prosthetic heart valves. Stroke. 1998. 29:1770–1777.

20. Feinberg WM, Bruck DC, Jeter MA, Corrigan JJ Jr. Fibrinolysis after acute ischemic stroke. Thromb Res. 1991. 64:117–127.

21. Takada A, Takada Y, Urano T, Sakakibara K, Shozuhara H, Toyama K. Changes in plasma levels of t-PA, PAI-1 and t-PA-PAI-1 complex in patients with cerebrovascular thrombosis infused with t-PA. Thromb Res. 1990. 59:375–381.

22. Bick RL, Murano G. Physiology of hemostasis. Clin Lab Med. 1994. 14:677–707.

23. Akira S, Hirano T, Taga T, Kishimoto T. Biology of multifunctional cytokines: IL 6 and related molecules (IL 1 and TNF). FASEB J. 1990. 4:2860–2867.

24. Libby P, Ordovas JM, Auger KR, Robbins AH, Birinyi LK, Dinarello CA. Endotoxin and tumor necrosis factor induce interleukin-1 gene expression in adult human vascular endothelial cells. Am J Pathol. 1986. 124:179–185.

25. Woodroofe MN, Sarna GS, Wadhwa M, Hayes GM, Loughlin AJ, Tinker A, et al. Detection of interleukin-1 and interleukin-6 in adult rat brain, following mechanical injury, by in vivo microdialysis: evidence of a role for microglia in cytokine production. J Neuroimmunol. 1991. 33:227–236.

26. Clark WM, Rinker LG, Lessov NS, Hazel K, Hill JK, Stenzel-Poore M, et al. Lack of interleukin-6 expression is not protective against focal central nervous system ischemia. Stroke. 2000. 31:1715–1720.

27. Araujo DM, Cotman CW. Transient neurotrophic effects of interleukins on hippocampal neurons in vitro (abstract). IIIrd IBRO World Congress of Neuroscience;243.

28. Giulian D, Lachman LB. Interleukin-1 stimulation of astroglial proliferation after brain injury. Science. 1985. 228:497–499.

29. Strieter RM, Kunkel SL, Showell HJ, Remick DG, Phan SH, Ward PA, et al. Endothelial cell gene expression of a neutrophil chemotactic factor by TNF-α, LPS, and IL-1β. Science. 1989. 243:1467–1469.

30. Johansson A, Ahren B, Nasman B, Carlstrom K, Olsson T. Cortisol axis abnormalities early after stroke--relationships to cytokines and leptin. J Intern Med. 2000. 247:179–187.

31. Vila N, Castillo J, Davalos A, Chamorro A. Proinflammatory cytokines and early neurological worsening in ischemic stroke. Stroke. 2000. 31:2325–2329.

32. Stouthard JM, Levi M, Hack CE, Veenhof CH, Romijin HA, Sauerwein HP, van der Poll T. Interleukin-6 stimulates coagulation, not fibrinolysis, in humans. Thromb Haemost. 1996. 76:738–742.

33. Aso Y, Okumura K, Yoshida N, Tayama K, Kinda T, Kobayashi I, et al. Plasma interleukin-6 is associated with coagulation in poorly controlled patients with type 2 diabetes. Diabet Med. 2003. 20:930–934.

34. Conrad MF, Stone DH, Albadawi H, Hua HT, Entabi F, Stoner MC, et al. Local inflammatory and thrombotic response differ in a murine model of partial and complete hindlimb ischemia/reperfusion. Surgery. 2005. 138:375–381.

35. Derhasching U, Bergmair D, Marsik C, Schlifke I, Wijdenes J, Jilma B. effect of interleukin-6 blockade on tissue fator-induced coagulation in human endotoxemia. Crit Care Med. 2004. 32:1136–1140.